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Subcortical vascular dementia is a clinical entity, widespread, even challenging to diagnose and correctly treat. Patients with this
diagnosis are old, frail, often with concomitant pathologies, and therefore, with many drugs in therapy. We tried to diagnose
and follow up for three years more than 600 patients. Study subjects were men and women, not bedridden, aged 68–94
years, outpatients, recruited from June, 1st 2007 to June, 1st 2010. We examined them clinically, neurologically, with speciﬁc
consideration on drug therapies. Our aim has been to deﬁne gait and imbalance problem, if eventually coexistent with the




in the elderly and are related to loss of functional inde-
pendence and death. Cerebral small vessel disease is related
to gait disturbances: in particular, white matter lesions and
lacunar infarcts were both independently associated with
most gait parameters, in particular with stride length [1].
These authors concluded that white matter lesions in the
basal ganglia and internal capsule and limbic areas and
lacunar infarcts in the frontal lobe and thalamus were
related to a lower velocity [1]. It has been established
recently a direct relationship between subcortical vascular
lesions and falls, even if works on the matter are scarce [2–
4]. Age-related cerebral degenerative changes are coupled
therefore with decreased perfusion, usually assumed to be
secondary to decreased cerebral metabolic demands [5].
During ageing declines in cerebral tissue densities in gray
(polio-araiosis) and white matter (leukoaraiosis) reﬂect neu-
ronal degenerative changes, which progress concurrent with
cerebral perfusion declines. Rates of polio- and leukoaraiosis
accelerategeometricallyafterage60,correlatingwithcortical
and subcortical atrophy and ventricular enlargement. In
particular, leukoaraiosis correlates with advancing age, cere-
bral atrophy, hypoperfusion of white matter, and cognitive
impairments [6]: what is surprising is that leukoaraiosis
is detectable in 9–19% of older “normal” subjects but is
virtually always present in vascular dementia. Of special
interest are the data emerging from the study of Meyer et al.
[6]: normative subjects destined for later cognitive decline
had excessive leukoaraiosis at study entry, suggesting that
leukoaraiosis is, itself, a risk factor for cognitive decline. Vas-
cular dementia refers to a broad category of patients where
a multifaceted cognitive decline is attributed to cerebro-
or cardio-vascular disease. It has long been known that
cognitive deﬁcits may result from a stroke, yet only recently
have reports demonstrated that dementia may occurs in
approximately one-fourth to one-third of stroke cases [7].
Apart from that dementia is due to single strategic infarcts
seated in critical areas, such as hippocampus, thalamus,
and caudate nucleus, and to intracranial hematomas or
mixedforms,vasculardementia(VaD)isalsoassociatedwith
subcortical ischemic vascular disease caused by small-vessel
disease leading to lacunar infarcts and ischemic white matter
changes. Only recently, the International Classiﬁcation of
Diseases (10th revision) (ICD-10) criteria for VAD explicitly
identiﬁed subcortical VaD as a subgroup [8]. Subcortical
VaD, therefore, incorporates the old entities “lacunar state”
and “Binswanger disease” and relates to small vessel disease
and hypoperfusion resulting in focal and diﬀuse ischemic2 Current Gerontology and Geriatrics Research
white matter lesion and incomplete ischemic injury [9, 10].
Two pathophysiological mechanisms, sharing common risk
factors, lead to dementia associated with small-artery disease
[11]: one possible mechanism is deﬁned by occlusion of an
arteriallumen,whichconductstoacompleteinfarct(lacunar
infarct) and leads to dementia due to the disruption of a
neural pathway. The other mechanism involved is deﬁned
by critical stenosis and hypoperfusion of multiple arterioles.
This results in widespread areas of incomplete infarction of
the deep white matter and consequent functional disruption
of neural network. The end stages of the two pathways are
labeled as lacunar state and Binswanger syndrome, which, in
practice, usually converge.
Cerebrovasculardiseaseiscommontotheelderlyandcan
cause a wide spectrum of impairments ranging from mild
to severe. Sensitive and speciﬁc deﬁnitions of cerebrovas-
cular cognitive impairment are hampered by the fact that
cerebrovascular disease is not easily linked to cognitive syn-
dromes either clinically or pathologically and the presence
of coincident AD is common. In a well-deﬁned population
suﬀering from subcortical vascular dementia (standing from
a neurological, clinical, and radiological criteria) we have
tried to deﬁne gait, balance, and equilibrium alterations,
even considering precipitant factors, such as concomitant
pathologies and consequent therapies.
2.SubjectsandMethods
2.1. Methods
2.1.1. Patients. Study subjects were men and women aged
68–94 years, entering in Cognitive Disorder Unit Evalua-
tion of the University of Trieste, with Mini-Mental State
Examination (MMSE) scores of at least 14 and satisfying
the fourth edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) for dementia, recruited
from June 1st 2007 to June 1st 2010. We have examined
2345 patients, who have been diagnosed as suﬀering from
mild cognitive impairment, Alzheimer’s Disease, frontal lobe
dementia, Lewy body dementia and Parkinson-dementia
complex. 817 patients suﬀered from vascular dementia, and
171 have been diagnosed as having multi-infarct dementia.
To this group belonged 21 patients suﬀering primarily from
brainstem infarction. 646 patients suﬀered from subcortical
vascular dementia: these study subjects satisﬁed the criteria
for probable VaD in accordance with the NINDS-AIREN
criteria (Rom´ an et al., 1993). A patient was diagnosed as
having subcortical VaD (sVaD) when the CT/MRI scan
showed moderate to severe ischaemic white matter changes
(Erkinjuntti et al., 1999) and at least one lacunar infarct.
Brain CT scans or MRI images were randomized and
assessed independently, after the radiologist’s opinion, by
neurologists (RM, PT).
Patients were not included in the study if they showed
signs of normal pressure hydrocephalus, previous brain
tumours, previous diagnosis of major stroke or brain
haemorrhage. We did not include patients with white matter
lesions, caused by speciﬁc aetiologies, such as multiple
sclerosis, brain irradiation, collagen vascular disease, and
Table 1: Baseline characteristics of patients.
Age in years (mean ± SD) 73.45 ±7.12
Gender (male/female) 304/302
Education level in years (mean ± SD) 9.45 ±1.1
Concomitant illnesses (N.+ % patients)
Essential hypertension 189 (31.18%)
Diabetes mellitus, type 2 236 (38.94%)
Ischaemic cardiopathy/valvular failure/arrythmias 149 (24.58%)
Chronic obstructive bronchopathy 179 (29.53%)
Neoplasia 23 (3.79%)
genetic forms of vascular dementia (such as CADASIL
or CARASIL). Patients with previous major psychiatric
illness (i.e., schizophrenia, bipolar disorders, psychosis,
compulsive-obsessive disorders, etc.) or central nervous
system disorders and alcoholism were excluded too. We did
not consider a discriminant/exclusion criteria depression,
according to diﬀerent studies (such as [12]), according to
the potential correlation to vascular dementia predisposing
factor.
2.1.2. Study Design. This was a prospective cohort study,
designed to investigate gait (balance and equilibrium) dis-
orders, behavioural alterations, drug intake of a subcortical
dementia population. Study subjects were 646 men and
women, diagnosed as previously stated as subcortical vas-
cular dementia (sVaD), not bedridden, aged 68–94 years
outpatients, recruited from June, 1st 2007 to June, 1st
2010, who underwent a standardized baseline assessment
that included a detailed history, a physical examination,
laboratory tests, and psychiatric evaluations. The physical
examination included evaluations of pulse rate and rhythm,
bloodpressure,heartsizeandsounds,peripheralpulses,reti-
nal vessel and carotid artery evaluation, electrocardiographic
evaluation, and chest X-ray. The physical examination was
repeated at every visit; electrocardiographic evaluation and
laboratory tests were repeated every 12 months. Patients in
both groups were allowed to continue any previous therapy
(e.g., cholinesterase inhibitors, antihypertensive, antidyslipi-
demic, antidiabetic drugs). (Table 1). All patients were fol-
lowed with periodical neurological and neuropsychological
examinations. Visits were scheduled to take place every
four months. A complete neuropsychological examination
was conducted at baseline and every 6 months; every 12
months’ results were compared. The trial was conducted in
accordance with the Declaration of Helsinki and with the
Ethics Guidelines of the Institute.
2.1.3. Outcome Measures. Global performance was assessed
using the Clinical Dementia Rating (Hughes et al., 1982)
at every visit. Behavioural symptoms were assessed using
the Neuropsychiatric Inventory (NPI) (Cummings et al.,
1994) at every visit. Functional activities were assessed by
the Barthel index (BI) (Mahoney and Barthel, 1965), and
complex activities of daily living were evaluated by the
Instrumental activity of Daily living (IADL) (Lawton and
Brody, 1969). Mobility problems were assessed by the TinettiCurrent Gerontology and Geriatrics Research 3
scaleforequilibrium/balanceandgait(Tinetti,1986)atevery
visit. Semiquantitative assessment consisted of the modiﬁed
Tinetti test with 17 items: 9 for body balance (score 0 to
16) and 8 for gait (score 0 to 12) with a maximum score of
28. Hachinski Ischemic score (HIS) was done at every visit
(Hachinski et al., 1975). Patients were registered for their
medical intake.
2.1.4.StatisticalAnalyses. Statisticalanalyseswereperformed
using the Statistical Package for the Social Sciences (SPSS,
version 16.0). Within-group changes from baseline to 12, 24,
and 36 months were tested using the Wilcoxon Signed Ranks
test. This was done for the overall scores for each eﬃcacy
variable.
Spearman’s rank correlation analyses were performed
between behavioral outcome measures, Tinetti scale, global,
balance and equilibrium, and BI. Results are presented as
mean changes from baseline with standard deviations, and
P values are presented where appropriate.
3. Results
Among 2345 patients, 817 were diagnosed as having vascular
dementia: 171 did have multi-infarct dementia, and 646
patients had subcortical vascular dementia; the latter, 320
men and 326 women, were included in the study (Table 1).
Their mean age was 73.45 ± 7.12 years, and they had a mean
education level of 9.45 ± 1.19 years.
The diagnosis was based on historical information and
neuropsychologicalassessmentandsupportedbyﬁndingson
structural (CT or magnetic resonance) imaging. Subsequent
follow-up of subjects has reinforced the clinical diagnoses in
all cases.
Brain CT scans or MRI images were available for all
the 646 selected patients; 246 patients did MRI studies, and
456 did CT scans. Obviously, the sensitivity for observing
subcortical lesions is greater with MRI compared to CT
scans. Though, considering that all the patients went to
our unit for a specialist evaluation and eventual follow-
up by their general practitioners, it was obvious that
they prescribed more easily CT scans rather than MRI
imaging. For 400 patients, CT scans, history, neurological,
and neuropsychological tests were sensitive and suﬃcient
to make the diagnosis. 56 patients were requested by us
to complete their diagnostic route with MRI sequences, in
case of not adequate imaging acquisition or not convincing
data. 190 patients came to our unit with MRI images,
prescribed by their general practitioners or by diﬀerent
specialists who they attended before our visit. Therefore, the
patients who did CT/MRI were homogeneously recruited,
and no demographical/social/ cultural/clinical diﬀerence
distinguishes them from each other.
Two neurologists of the group revised all the imaging,
employing the Blennow et al. [13] scale for CT scans and the
Scheltens et al. [14] scale for MRI imaging. There was 96.7%
interrater agreement for the independent assessment of the
scans (kappa = 0.79).
Twenty four patients died during follow-up; sixteen
patients did not have a caregiver, who could guarantee
adequate compliance and therefore have been excluded, after
the ﬁrst year from the study. All the other 606 patients
(304 men and 302 women) completed the full 36-month
study.Patientswereallowedtocontinueanyprevioustherapy
(e.g., antihypertensive, antidyslipidemic, antidiabetic drugs)
(Table 2). During the follow-up, the patients were prescribed
neuroleptics and/or benzodiazepines (Table 3).
Considering the global health conditions, there was an
obvious deterioration in the patients as evidenced by the
increase of the daily drug uptake (Table 3).
Main scores obtained by the patients, during the follow-
up, have been reported in Table 4 as mean and SD. Particu-
larly, the results obtained in the Tinetti Scale, considered as
subscores gait and equilibrium, as said before, and the total
score,havebeenreportedinTable 5.AccordingtoaWilcoxon
Signed Ranks test, there was a general worsening of the clini-
cal,cognitive,behavioural,andinstrumentalcapacitiesofthe
patients observed in the 36 months of follow-up (Table 6).
Moreover, there was a dramatic decrease in gait and equilib-
rium control in the patients during follow-up (Table 7). In
particular,weobservedasigniﬁcantdecreaseinTinettiglobal
scores (and separate subitems) in the diabetic group (263
patients) and in the cardiopatic patients (149). In particular,
as far as 102 patients suﬀered of the two conditions at the
sametime,theirTinettiscoresaretheworst(signiﬁcantlydif-
ferent from the scores obtained by 162 patients who suﬀered
from diabetes only (P<. 01) and from the scores done by the
47 patients (P<. 05) who suﬀered from cardiac pathologies.
Spearman’s rank correlation analyses indicated that there
was a signiﬁcant correlation between gait scores (total and
separately, gait and equilibrium) and Clinical Dementia
Rating Scales scores (CDR = 2.13 ± 0.11, r = 0.81, P<. 05
over 12 months; CDR = 2.84 ± 0.4, r = 0.83, P<. 01 over
24 months; CDR = 2.98 ± 0.61, r = 0.89, P<. 01 over
36 months). Spearman’s rank correlation analyses indicated
that there was a signiﬁcant correlation between Tinetti gait
score and BI over 24 months (BI = 76.84 ± 6.11, r = 0.72,
P<. 05), Tinetti equilibrium score and BI over 36 months
(BI = 61.17 ± 7.3, r = 0.71, P<. 01), and Tinetti gait score
and BI over 36 months (BI = 61.17 ±7.3, r = 0.78, P<. 01).
Moreover, we have found a correlation between NPI scores
and Tinetti gait score over 24 months (NPI = 56.84 ± 12.11,
r = 0.81, P<. 01), Tinetti equilibrium score and NPI over 36
months (NPI = 66.03 ± 8.81, r = 0.87, P<. 01), and Tinetti
gait score and NPI over 36 months (NPI = 66.03 ± 8.81,
r = 0.78, P<. 01), and of course, Tinetti total score and
NPI over 36 months (NPI = 66.03±8.81, r = 0.93, P<. 01).
Surprisingly, we have found only a correlation between
benzodiazepines intake and Tinetti equilibrium score at 12,
24,and36months(resp.,r = 0.77,P<. 05;r = 0.78,P<. 05;
r = 0.67, P<. 05 at 12 months; r = 0.81, P<. 01; r = 0.77,
P<. 05; r = 0.84, P<. 01 at 24 months; r = 0.81, P<. 01;
r = 0.82, P<. 01; r = 0.89, P<. 01 at 36 months).
Considering neuroleptics, one should take into account
the employment of typical or atypical neuroleptics. More-
over, quetiapine, as an atypical neuroleptic shows less
dopamine aﬃnity than olanzapine, which we have examined
through the study. Therefore, evaluating separately the
results, we have observed the following relationships.4 Current Gerontology and Geriatrics Research
Table 2: A synopsis of the drugs employed by the two groups of patients at baseline.
Drug utilization mg/day Baseline 12 months 24 months 36 months
ACE inhibitors 54 patients 89 patients 94 patients 164 patients
Enalapril, mean (±SD) dose 27. 4 ± 4.3 25.56 ± 3.65 25.56 ± 3.65 25.56 ± 3.65
Ramipril, mean (±SD) dose 3.41 ± 2.8 3.1 ± 1.89 3.1 ± 1.89 3.1 ± 1.89
Quinapril, mean (±SD) dose 5.11 ± 1.1 7.41 ± 0.8 7.6 ± 1.4 9.41 ± 1.8
Sartan 78 patients 67 patients 89 patients 102 patients
Losartan, mean (±SD) dose, 45.56 ± 23.54 49.67 ± 21.23 49.67 ± 21.23 49.67 ± 21.23
Telmisartan, mean (±SD) dose 43.12 ± 12.23 45.12 ± 1.45 40.2 ± 9.7 41.3 ± 9.6
Candesartan, mean (±SD) dose 16. 2 ± 2.32 16. 7 ± 6.16 12. 2 ± 5.65 14. 2 ± 4.32
Calcium antagonists 84 patients 93 patients 123 patients 153 patients
Amlodipine, mean (±SD) dose 6.0 ± 4.10 5.6 ± 2.34 5.6 ± 2.34 5.6 ± 2.34
Felodipine, mean (±SD) dose 7.5 ± 2.21 6.9 ± 3.5 6.9 ± 3.5 6.9 ± 3.5
Lacidipine, means (±SD) dose 4.5 ± 1.34 7.5 ± 0.21 7.67 ±1.3 5.56 ± 2.7
Antidiabetic medication 86 patients 112 patients 98 patients 105 patients
Glimepiride, mean (±SD) dose 1.0 ± 0.34 1.5 ± 0.56 1.43 ± 0.87 2.5 ± 0.12
Glibenclamide, mean (±SD) dose 5.5 ± 2.12 6.7 ± 1.43 7.5 ± 2.12 7.7 ± 3.5
Repaglinide, mean (±SD) dose 2.5 ± 0.34 2.65 ± 1.34 3.0 ± 1.31 4.0 ± 0.3
Metformina, mean (±SD) dose 950.5 ± 43.30 1200.5 ± 140.3 950.7 ± 443.3 1150.5 ± 153.3
Antiplatelet drugs 111 patients 149 patients 210 patients 249 patients
Ticlopidine, mean (±SD) dose 250mg, b.i.d 250mg b.i.d 250mg b.i.d 250mg b.i.d
ASA 117 patients 224 patients 326 patients 378 patients
Mean (±SD) dose 300 300 300 300
Digoxin 23 patients 25 patients 25 patients 25 patients
Mean (±SD) dose 0.23 ± 0.12 0.22 ± 0.13 0.22 ± 0.13 0.22 ± 0.13
Loop diuretics 53 patients 87 patients 78 patients 96 patients
Furosemide 29.45 ± 7.89 28.56 ± 8.92 28.56 ± 8.92 28.56 ± 8.92
Thiazide diuretics 65 patients 87 patients 93 patients 114 patients
Amiloride or hydrocnlorothiazide, mean (±SD) 14.7 ± 7.50 17.7 ± 3.50 17.7 ± 3.50 17.7 ± 3.50
Lipid lowering drugs 87 patients 124 patients 84 patients 84 patients
Torvastatin mean (±SD) dose 20.34 ± 8.76 21.34 ± 6.76 21.34 ± 6.76 21.34 ± 6.76
Simvastatin mean (±SD) dose 21.34 ± 7.67 22.43 ± 7.21 22.43 ± 7.21 22.43 ± 7.21
Pravastatin mean (±SD) dose 19.87 ± 8.67 24.54 ± 8.12 24.54 ± 8.12 24.54 ± 8.12
Nitroglycerine or analogue 126 patients 119 patients 139 patients 149 patients
Isosorbide mononitrate, mean (±SD) dose 36.67 ± 11.2 35.34 ± 10.56 35.34 ± 10.56 35.34 ± 10.56
Bronchodilators 59 patients 87 patients 97 patients 104 patients
Steroids, mean (±SD) dose 25.78± 11.2 31.8± 7.7 21.8± 6.5 31.8± 7.3
A combination of the above therapies 112 patients 183 patients 245 patients 345 patients
Table 3: A synopsis of the SNC drugs employed by the patients.
Drug utilization baseline 12 months 24 months 36 months
Benzodiazepines 44 patients 89 patients 98 patients 104 patients
lorazepam, mean (±SD) dose 1.27± 0.3mg/day 2.56 ± 0.65mg/day 3.94 ± 1.5mg/day 4.56 ± 1.65mg/day
delorazepam, mean (±SD) dose 1.21 ± 0.8mg/day 2.61 ± 1.29mg/day 3.1 ± 1.54mg/day 4.1 ± 1.89mg/day
bromazepam, mean (±SD) dose 2.11 ± 1.1mg/day 3.41 ± 0.8mg/day 4.6 ± 1.4mg/day 5.41 ± 1.8mg/day
Typical neuropletics 28 patients 56 patients 98 patients 167 patients
Haloperidol, mean (±SD) dose 1.56 ± 0.54mg/day 2.34 ± 0.67mg/day 2.87 ± 1.54mg/day 3.56 ± 0.54mg/day
promazine chloridate, mean (±SD) dose 53.12 ± 12.23mg/day 59.12 ± 16. 91mg/day 63.12 ± 7.2mg/day 67.12 ± 1.56mg/day
Atypical neurolpetics 4 patients 23 patients 63 patients 53 patients
olanzapine, mean (±SD) dose 4.0 ± 1.10mg/day 5.1 ± 2.34mg/day 5.6 ± 1.6mg/day 5.9 ± 2.94mg/day
quetiapine, mean (±SD) dose 37.5 ± 5.21mg/day 56.9 ± 3.5mg/day 66.8 ± 3.5mg/day 89.9 ± 3.5mg/dayCurrent Gerontology and Geriatrics Research 5
Table 4: Tests results in the patients observed during follow-up.
Tests Baseline 12 months 24 months 36 months
Clinical dementia rating 1.76 ±0.23 2.13 ±0.11 2.84 ± 0.42 .98 ±0.61
Neuro psychiatric inventory 24.45 ±7.25 41.84 ±2.13 56.84 ± 12.16 6 .03 ± 8.81
Barthel index 89.41 ±11.38 1 .14 ±0.11 76.84 ± 6.11 61.17 ±7.3
Instrumental activity of daily living 6.8 ±0.34 5.84 ±1.34 .67 ± 1.32 3.9 ±0.17
Hachinski ischemic score 7.6 ±0.16 .84 ±0.11 6.32 ± 0.36 .12 ±0.12
Table 5: Gait tests results in the patients observed during follow-up.
Tests Baseline 12 months 24 months 36 months
TINETTI equilibrium 10.1 ± 0.1 9.17 ± 0.7 8.27 ± 1.1 7.17 ± 1.7
TINETTI gait 11.7 ± 1.7 9.6 ± 0.9 9.2 ± 0.3 8.12 ± 0.13
TINETTI tot.score 21.8 ± 1.8 18.47 ± 1.4 17.7 ± 1.56 15.47 ± 1.6
Typical neuroleptics. We have found a signiﬁcant correlation
between haloperidol intake and Tinetti equilibrium score at
baseline and at 12 months (resp., r = 0.61, P<. 05 and
r = 0.72, P<. 05); between haloperidol intake and Tinetti
total score at 24 and 36 months (resp., r = 0.81, P<. 01
and r = 0.86, P<. 01); not signiﬁcant correlation between
promazinechloridateintakeandTinettisubscoresatbaseline
and at 12 months; we have found a positive correlation
between the equilibrium score of Tinetti test and promazine
intake at 24 months (r = 0.74, P<. 05) and a positive
correlation between the equilibrium score and the gait score
of Tinetti test and promazine intake at 36 months (resp.,
r = 0.79, P<. 01 and r = 0.81, P<. 01).
Atypical Neuroleptics. We have found a signiﬁcant correla-
tionbetweenolanzapineintakeandTinettiequilibriumscore
at 12 and at 24 months (resp., r = 0.61, P<. 05; r = 0.68,
P<. 05); between olanzapine intake and Tinetti total score
at 36 months (resp., r = 0.71, P<. 05); we have found a
positive correlation between the equilibrium score of Tinetti
test and quetiapine intake at 24 and at 36 months (resp.,
r = 0.77, P<. 05; r = 0.80, P<. 01). The mean dose
of olanzapine remained stable during the 12th up to the
36th months of follow-up (5.1–5.9mg/day); on the contrary,
quetiapine dosage increased during up to 36th months of
follow-up (56.9–89.9mg/day).
4. Discussion
Walking is a complex mechanism, based on motor con-
trol, step rhythm, muscular activation and dysactivation,
motor adjustment, attention, perception, and so on. Spinal
and brainstem activation, which seem to be fundamen-
t a lf o rq u a d r u p e d s ,i nh u m a n sd e p e n dm o r eo nc o r t i c a l
and subcortical inputs in humans [15]. Therefore, it has
been hypothesized that the association between step length
variability and basal ganglia integrity is consistent with
our knowledge of the role played by the basal ganglia in
controlling mobility, because of their functional connection
with the other motor areas, the basal ganglia control motor
coordination and rhythmicity [16, 17]. As well pointed oﬀ
in the study by Rosano et al. [16], the basal ganglia exerts
a compensatory mechanism in gait control, in particular
in gait variability. In their study, subclinical brain vascular
abnormalities were measured on brain MRI as infarcts
and white matter hyperintensities. They demonstrated that
greater variability of step length was associated with greater
prevalence of infarcts and greater white matter hyperinten-
sities severity, independent of age, gender, and cognitive
function [16] To implement these data, another study by
Carboncini et al. [15] demonstrated that higher level gait
disorders are a common gait alteration in older people and
that gait disorders can occur in a neurological syndrome
namedasleukoaraiosis.Theirperfusionalfunctionalcerebral
SPECT demonstrated that the rCBF increase induced by
the treadmill test (functional versus baseline), bilaterally in
the medial frontal gyrus and in the anterior lobes of the
cerebellum, resulted signiﬁcantly lower in patients with gait
apraxia versus those without it, all of them having diﬀused
chronic ischemic lesions within white matter [15]. Data have
beenclinicallyconﬁrmedbyotherworksbytheLADISgroup
[4], by Srikanth et al. [18], and by Masdeu and Wolfson [19].
The results of our study might be considered at ﬁrst
instance as not unexpected and not completely novel.
Though, trying to evaluate them, step by step, we could
considerthattheyaretheﬁrstresultsongaitandequilibrium
in a selected subcortical vascular dementia population, with
a 36-month follow-up. Our prospective evidence demon-
strates that in a selected subcortical vascular dementia
group, diagnosed either accomplishing neurological or neu-
roimaging criteria, there is major evidence of signiﬁcant
gait and equilibrium problems, from the beginning of the
observational period, and they become worse during the
three years of follow-up. A clear point should be made
standing from the ﬁrmly exclusion criteria of brainstem
lesions, in order to eliminate potential confounding eﬀect of
speciﬁc ischemic lesions on gait and equilibrium. Therefore,
gait and balance alterations observed in this population
should be considered as a result of subcortical widespread
damage, and not of other problems, such as pharmacological
eﬀects or superimposing comorbidities; during follow-up,
the gait abnormalities are stressed by the general worsening,6 Current Gerontology and Geriatrics Research
Table 6: Results at 36 months: a comparison over 12 and 24 months.
Tests at 36 months Over baseline Over 12 months Over 24 months
Clinical dementia rating +1.22 ± 0.4 P<. 01 +0.85 ± 0.2ns +0.14 ± 0.21ns
NeuroPsychiatric inventory +31. 58 ± 6.4 P<. 01 +24.19 ± 5.9 P<. 01 +9.19 ± 5.9 P<. 01
Barthel index −28.04 ± 3.4 P<. 01 −25.17± 3.4 P<. 01 −13.57 ± 3.4 P<. 05
Instrumental activity of daily living −2.1 ± 1.2 P<. 05 −1.7 ± 0.3 P<. 05 −0.4 ± 3.4ns
Hachinski ischemic score −1.18 ± 0.2 P<. 05 −0.7 ± 0.3ns −0.2 ± 0.1ns
Table 7: Results of gait scores at 36 months: a comparison over 12 and 24 months.
Tests at 36 months Over baseline Over 12 months Over 24 months
TINETTI equilibrium −3.1 ± 0.6 P<. 01 −2 ± 1.01 P<. 01 −1.1. ± 0.6 P<. 05
TINETTI gait −3.5 ± 1.4 P<. 01 −1.5 ± 0.7 P<. 05 −1.1. ± 0.1 P<. 05
TINETTI tot.score −6.47 ± 0.2 P<. 01 −3 ± 0.1 P<. 05 −2.3 ± 0.4 P<. 05
the decrease of behavioural control, and the consequent
neuroleptic and benzodiazepine intake.
Therefore, it might be concluded that subcortical lesions,
perse,causeimbalanceandgaitalteration:wemighthypoth-
esize that this subcortical hypoperfusion might interrupt
long loop reﬂexes of deep white motor tracts and descending
motor ﬁbers arising from medial cortical areas (see data and
literature in: [3, 20]); moreover, subcortical vascular lesions
interest ﬁbres connecting frontal cortex and subcortical
structures, which are responsible for motivation, executive
function, planning, and attention too (see in particular
frontal eye ﬁelds). It has been suggested (see data and
literature in [20]) that the basal ganglia maintains cortically
selected motor set in the supplementary motor area and
provides internal cues to the supplementary motor area in
order to enable each submovement to be correctly linked
together Iansek et al. [21]. It has been demonstrated that
attention problems, in particular of shift attention and
focused attention, decrease the performance of gait in
Parkinsonian patients with freezing of gait [22–24].
These data seem to be in accordance with what we
observed, at baseline: subcortical demented patients might
show gait problems just for their vascular altered white
substance. However, it must be considered that our sub-
cortical vascular population is not a mathematical model.
The follow-up of the pathology is tightly connected with
the general worsening of health condition, which conduct
to a deterioration of gait in diﬀerent ways: due to general
strengthdiminishment,badtolerancetophysicaleﬀort(such
as in cardiac pathologies), or due to an evident alteration of
glucose metabolism, with consequent peripheral alterations
(polyneuropathy, peripheral arterials alterations), and/or
bad resistance to muscular eﬀorts.
On the other hand, the evolution of subcortical dementia
l e a d st ob e h a v i o u r a la l t e r a t i o n ,a sw e l la sc o g n i t i v ei m p a i r -
ment worsening (in particular of executive function and
frontal focusing). The former imposes a speciﬁc therapy,
based on sedative and neuroleptic drugs. They might be
relatedtohypotonia,alteredbalance,reducedposturalreﬂex,
static imbalance, parkinsonism, and so forth. All these
aspects worsenthe gait proﬁle,as documented by our results.
Moreover, in an old and sensitive population, like the one
considered in this study even the generally considered safest
drug, such as atypical neuroleptics (and among them, even
thelessdopaminereceptoraﬃne,asquetiapine),mightcause
unexpected but signiﬁcant alteration of balance and gait,
p r o b a b l yd u et ot h eg e n e r a lf a v o u r a b l eg r o u n dd e t e r m i n e d
by the primary brain condition.
All these facts considering subcortical vascular dementia
may be associated with gait and balance alteration perse;
its worsening and the pharmacological choices, imposed by
the evolution of the pathology, should be considered by the
clinicians in order to prevent major gait alteration, falls, and
postural imbalance, or at least, to reduce their consequence
in a real frail population.
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